FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310096578> ?p ?o ?g. }

• W4310096578 endingPage "11787" @default.
• W4310096578 startingPage "11786" @default.
• W4310096578 abstract "Introduction WT1 mRNA levels assessed by q-PCR have been employed as a marker of remission in AML patients undergoing intensive chemotherapy (Nomdedeu J. et al. Leukemia 2013;27:2157) and hematopoietic cell transplantation (HCT) (Nomdedeu J et al. Biol Blood Marrow Transplant 2018;24:55). Patients with adjusted bone marrow WT1 mRNA levels greater than 100 copies showed a high probability of relapse. Despite the usefulness of WT1 quantification in this and other settings, this marker is scarcely employed as an MRD target because levels greater than >100 copies can also be observed in normal bone marrows. Furthermore, 10-20% of AML at diagnosis and most chronic myelomonocytic leukemia (CMML) cases lack WT1 upregulation. The high levels of bone marrow WT1 copy numbers observed in most AML, decline in responding patients, although the utility, if any, of WT1 levels in long-term survivors of AML is currently unknown. We investigated the frequency and biological findings of mCR AML samples showing WT1 upregulation(>100 copies) compared to that mCR AML with concordant low WT1 levels. Patients and methods The study included 717 bone marrow samples from 80 AML patients (23 patients with RUNX1-RUNX1T1, 18 pts with CBFb-MYH11, four pts with NPM1 mutations, and 35 pts with PML-RARa). Samples were obtained at diagnosis (58 samples) and the follow-up (659 samples, all in mCR and without relapses) from one month to 219 months after diagnosis. Chimeric transcripts and WT1 levels were investigated by standardized real-time methods (ELN). Hemoglobin and leukocyte counts were also recorded. Flow cytometry immunophenotyping was also performed using four-color flow cytometry. We analyzed the percentage of CD34+, CD117+, CD123+ cells, and the Myeloid/Lymphoid CD34 ratio. nCounter Stem cell panel (Nanostring) was used to investigate the differences between that AML in mCR, showing high (>100) and low (<100) WT1 levels. In an additional cohort (11 samples: 4 with WT1>100 and 7 with WT1 <100), we performed bulk RNAseq (Novogene) to investigate enriched genes in samples with high WT1 levels. Results Thirty-five patients had at least one sample with WT1 levels greater than 100 copies (44%) despite being in mCR. Twelve samples had WT1 levels greater than 300 copies. In one case, this level reached 770 copies. These WT1 peak samples were distributed as follows: 49/306 PML-RARa, 25/161 RUNX1-RUNX1T1, 10/174 CBFb-MYH11, and 1/18 NPM1. Patients showing WT1 peaks were older than those without elevations (47 years vs. 36 years, p:0.003) For PML-RARa samples, peaking was associated with low levels of hemoglobin (133 g/L for <100 copies vs. 125 g/L >100 copies, p:0.009). For RUNX1-RUNX1T1, peaking was linked to less platelets (132x109 vs. 197x109 p:0.05) , higher CD34 (1.5% vs. 1% p:0.05) and also higher CD117+ cells (1.6 vs.1%, p:0.01). Lastly, CBFb-MYH11+ samples with WT1 peaks had higher leukocyte counts that those showing low WT1 levels (4.5x109 vs. 2.9x109, p:0.006). Nanostring comparisons between mCR WT1 high vs. low samples showed upregulation of TOR1A, PIK3CB, PTPN6, and PGM1 with downregulation of HMGA1, HOXB2 and CDC6. RNA seq analysis detected an enrichment of SUZ12 targets in those samples with high WT1 levels. Conclusions Bone marrow mRNA WT1 levels commonly exceed the clinical relevant value of 100 copies in AML samples in mCR (13%). Peak samples were related to peripheral blood values and/or raised numbers of immature bone marrow cells (CD34, CD117). Bone marrow WT1 although unable to accurately predict relapses in long-term survivors of AML may be a non-invasive sensor of a yet undefined myeloid state." @default.
• W4310096578 created "2022-11-30" @default.
• W4310096578 creator A5004971949 @default.
• W4310096578 creator A5011730823 @default.
• W4310096578 creator A5012925920 @default.
• W4310096578 creator A5016773523 @default.
• W4310096578 creator A5027357638 @default.
• W4310096578 creator A5038627497 @default.
• W4310096578 creator A5043591698 @default.
• W4310096578 creator A5045381644 @default.
• W4310096578 creator A5048538455 @default.
• W4310096578 creator A5073899064 @default.
• W4310096578 creator A5081467134 @default.
• W4310096578 date "2022-11-15" @default.
• W4310096578 modified "2023-10-08" @default.
• W4310096578 title "Bone Marrow WT1 mRNA Upregulation in Acute Myeloid Leukemia (AML) in Complete Molecular Remission (mCR): Understanding the Limitations and Advantages of WT1 As a Measurable Residual Disease (MRD) Target" @default.
• W4310096578 doi "https://doi.org/10.1182/blood-2022-166117" @default.
• W4310096578 hasPublicationYear "2022" @default.
• W4310096578 type Work @default.
• W4310096578 citedByCount "0" @default.
• W4310096578 crossrefType "journal-article" @default.
• W4310096578 hasAuthorship W4310096578A5004971949 @default.
• W4310096578 hasAuthorship W4310096578A5011730823 @default.
• W4310096578 hasAuthorship W4310096578A5012925920 @default.
• W4310096578 hasAuthorship W4310096578A5016773523 @default.
• W4310096578 hasAuthorship W4310096578A5027357638 @default.
• W4310096578 hasAuthorship W4310096578A5038627497 @default.
• W4310096578 hasAuthorship W4310096578A5043591698 @default.
• W4310096578 hasAuthorship W4310096578A5045381644 @default.
• W4310096578 hasAuthorship W4310096578A5048538455 @default.
• W4310096578 hasAuthorship W4310096578A5073899064 @default.
• W4310096578 hasAuthorship W4310096578A5081467134 @default.
• W4310096578 hasConcept C104317684 @default.
• W4310096578 hasConcept C109159458 @default.
• W4310096578 hasConcept C126322002 @default.
• W4310096578 hasConcept C143998085 @default.
• W4310096578 hasConcept C203014093 @default.
• W4310096578 hasConcept C2483381 @default.
• W4310096578 hasConcept C2777408962 @default.
• W4310096578 hasConcept C2777928532 @default.
• W4310096578 hasConcept C2778461978 @default.
• W4310096578 hasConcept C2778729363 @default.
• W4310096578 hasConcept C2779282312 @default.
• W4310096578 hasConcept C2779823535 @default.
• W4310096578 hasConcept C2780007613 @default.
• W4310096578 hasConcept C2780817109 @default.
• W4310096578 hasConcept C28328180 @default.
• W4310096578 hasConcept C2911091166 @default.
• W4310096578 hasConcept C30481170 @default.
• W4310096578 hasConcept C53226629 @default.
• W4310096578 hasConcept C54355233 @default.
• W4310096578 hasConcept C55493867 @default.
• W4310096578 hasConcept C71924100 @default.
• W4310096578 hasConcept C86803240 @default.
• W4310096578 hasConceptScore W4310096578C104317684 @default.
• W4310096578 hasConceptScore W4310096578C109159458 @default.
• W4310096578 hasConceptScore W4310096578C126322002 @default.
• W4310096578 hasConceptScore W4310096578C143998085 @default.
• W4310096578 hasConceptScore W4310096578C203014093 @default.
• W4310096578 hasConceptScore W4310096578C2483381 @default.
• W4310096578 hasConceptScore W4310096578C2777408962 @default.
• W4310096578 hasConceptScore W4310096578C2777928532 @default.
• W4310096578 hasConceptScore W4310096578C2778461978 @default.
• W4310096578 hasConceptScore W4310096578C2778729363 @default.
• W4310096578 hasConceptScore W4310096578C2779282312 @default.
• W4310096578 hasConceptScore W4310096578C2779823535 @default.
• W4310096578 hasConceptScore W4310096578C2780007613 @default.
• W4310096578 hasConceptScore W4310096578C2780817109 @default.
• W4310096578 hasConceptScore W4310096578C28328180 @default.
• W4310096578 hasConceptScore W4310096578C2911091166 @default.
• W4310096578 hasConceptScore W4310096578C30481170 @default.
• W4310096578 hasConceptScore W4310096578C53226629 @default.
• W4310096578 hasConceptScore W4310096578C54355233 @default.
• W4310096578 hasConceptScore W4310096578C55493867 @default.
• W4310096578 hasConceptScore W4310096578C71924100 @default.
• W4310096578 hasConceptScore W4310096578C86803240 @default.
• W4310096578 hasIssue "Supplement 1" @default.
• W4310096578 hasLocation W43100965781 @default.
• W4310096578 hasOpenAccess W4310096578 @default.
• W4310096578 hasPrimaryLocation W43100965781 @default.
• W4310096578 hasRelatedWork W1972850129 @default.
• W4310096578 hasRelatedWork W2079966689 @default.
• W4310096578 hasRelatedWork W2121159001 @default.
• W4310096578 hasRelatedWork W2156781830 @default.
• W4310096578 hasRelatedWork W2161184668 @default.
• W4310096578 hasRelatedWork W2360105106 @default.
• W4310096578 hasRelatedWork W2401840403 @default.
• W4310096578 hasRelatedWork W2791018567 @default.
• W4310096578 hasRelatedWork W2964895539 @default.
• W4310096578 hasRelatedWork W4206184667 @default.
• W4310096578 hasVolume "140" @default.
• W4310096578 isParatext "false" @default.
• W4310096578 isRetracted "false" @default.
• W4310096578 workType "article" @default.